Business Context and Reporting Period
Company: Alto Neuroscience, Inc. (ANRO)
Filing Type: Form 8-K (Current Report)
Date of Report: October 19, 2025
Reporting Period: Events occurring on October 19 and October 20, 2025.
Context: The Company, an emerging growth company focused on neuroscience therapeutics, announced a private placement financing and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- Private Placement Proceeds: The Company anticipates gross proceeds of approximately $50.0 million from the private placement, before deducting offering expenses.
- Securities Issued:
- 3,832,263 shares of Common Stock.
- Pre-funded warrants to purchase 4,622,251 shares of Common Stock (issued in lieu of shares to certain purchasers).
- Pricing:
- Common Stock Purchase Price: $5.914 per share.
- Pre-Funded Warrant Price: $5.9139 per warrant (Purchase Price minus $0.0001).
- Pre-Funded Warrant Exercise Price: $0.0001 per share.
- Debt and Liquidity: The filing does not provide specific data on existing debt, cash flow, or liquidity positions outside of the anticipated proceeds from this transaction.
Material Changes and Agreements
- Entry into Material Definitive Agreement (Item 1.01): Entered into a Securities Purchase Agreement with institutional and accredited investors for the private placement described above.
- Termination of Material Definitive Agreement (Item 1.02): Terminated a Sales Agreement with Leerink Partners LLC (originally dated February 3, 2025, allowing for up to $75 million in sales). The termination is effective October 30, 2025. No shares were sold under this agreement prior to termination.
- Registration Rights: The Company agreed to file a registration statement within 45 days of closing to register the resale of the Common Stock and Warrant Shares.
Outlook, Management Commentary, and Risks
- Strategic Outlook: The Company announced plans to accelerate the development of ALTO-207 for the treatment of Treatment Resistant Depression following a successful outcome from a recent FDA meeting.
- Investor Limitations: Pre-Funded Warrants are subject to beneficial ownership limitations (generally capped at 19.9% unless adjusted with 61 days' notice).
- Risks and Contingencies:
- The securities were sold under Regulation D exemptions and have not been registered under the Securities Act of 1933.
- Representations and warranties in the Purchase Agreement are for risk allocation between parties and may not reflect materiality standards for general stockholders.
Key Facts for Investor Verification
- Verify the closing date and actual net proceeds received after deducting offering expenses.
- Confirm the filing and effectiveness of the registration statement for the resale of the new securities within the 45-day deadline.
- Review the full text of the press release regarding the FDA meeting outcome for ALTO-207 to assess the clinical development timeline.
- Monitor the dilution impact of the 3,832,263 shares and 4,622,251 pre-funded warrants on existing shareholders.